Drug Profile
Research programme: maytansinoid-antibody conjugates - Genentech
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genentech
- Class Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 25 Aug 2009 Preclinical development is ongoing in USA
- 09 Dec 2008 Genentech licenses the exclusive right to use ImunoGen's maytansinoid Tumor-Activated Prodrug (TAP) technology with Genentech antibodies